Inclusion Criteria:  In order to be eligible to participate in this study, a subject must meet all of the following criteria:  stable CAD with an indication for single antiplatelet therapy according to international (ESC) guidelines, high cardiovascular risk based on a SMART risk score [9] of at least 20% and/or the judgement of the cardiologist at least 1 year after myocardial infarction or multivessel CAD >16 years old Written informed consent  Exclusion Criteria:  A potential subject who meets any of the following criteria will be excluded from participation in this study:  Use of more intensive antithrombotic treatment (dual antiplatelet therapy, DPI, direct oral anticoagulants, vitamin k antagonists) Use of immunosuppressant and/or anti-inflammatory therapy, including glucocorticoids, cytostatics, antibodies, immunophilins, interferons, TNF binding proteins, mycophenolate and interleukin antagonists  Contra-indication to rivaroxaban  Hypersensitivity to rivaroxaban  at significant risk for major bleeding  current gastrointestinal ulceration presence of malignant neoplasms, with the exception of non-melanoma skin cancer recent (<2 months) brain or spinal injury recent (<3 months) brain or spinal surgery recent (<3 months) intracranial, gastrointestinal or pulmonary hemorrhage presence of arteriovenous malformations, major intraspinal or intracerebral vascular abnormalities congenital or acquired bleeding disorders uncontrolled severe arterial hypertension (180 mmHg or more systolic, or 110 mmHg or more diastolic) Severe hepatic disease: Child Pugh B or C [10] Severe kidney failure: estimated glomerular filtration rate<15 ml/min or requiring dialysis severe heart failure with known ejection fraction < 30% or New York Heart Association class III or IV symptoms [12] concomitant treatment with medication with a strong pharmacokinetic interaction with rivaroxaban, leading to contra-indication according to the "regionale_NOAC_richtlijn" [12] Pregnant or breastfeeding women Unable to give informed consent